-transparent.png){kind=logo}
As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn's disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Kunj Gohil, and
Brielle Carramusa
April 2008,
Journal of continuing education in nursing,
Kunj Gohil, and
Brielle Carramusa
December 2004,
La Revue du praticien,
Kunj Gohil, and
Brielle Carramusa
March 2014,
Revue de l'infirmiere,
Kunj Gohil, and
Brielle Carramusa
March 1960,
Canadian Medical Association journal,
Kunj Gohil, and
Brielle Carramusa
August 1994,
BMJ (Clinical research ed.),
Kunj Gohil, and
Brielle Carramusa
May 1967,
Lancet (London, England),
Kunj Gohil, and
Brielle Carramusa
January 2003,
Medicinski arhiv,
Kunj Gohil, and
Brielle Carramusa
December 2007,
La Revue du praticien,
Kunj Gohil, and
Brielle Carramusa
June 1970,
Lancet (London, England),
Kunj Gohil, and
Brielle Carramusa
December 2011,
La Revue du praticien,
